Diagnosis of hereditary platelet disorders in the era of next-generation sequencing: "primum non nocere"
- PMID: 30614196
- DOI: 10.1111/jth.14377
Diagnosis of hereditary platelet disorders in the era of next-generation sequencing: "primum non nocere"
Abstract
Inherited platelet disorders can affect "only platelets", occur as a "syndromic phenotype" or be associated with "increased risk of hematological malignancies". Genetic testing is attractive for diagnosis of inherited platelet disorders. However, many physicians who refer patient blood for genetic testing are unaware of the association of certain inherited platelet disorders with other risks. Inherited platelet disorders associated with minor-moderate bleeding rarely cause patient distress. In contrast, identification of a mutation associated with an increased risk of leukemia may cause a major psychological disease burden, without offsetting the beneficial impact on management. Guidelines recommend postponing genetic testing "until the patient reaches adulthood or at least until the child is mature enough to participate in decision making". In our opinion, outside research, (genetic) testing in children with inherited platelet disorders should only be performed if it influences management. In adults, genes causing inherited platelet disorders associated with an increased risk of hematological malignancies should only be tested after obtaining explicit informed consent.
Keywords: genetics; hereditary platelet disorders; next-generation sequencing; platelets; thrombocytopenia.
© 2019 International Society on Thrombosis and Haemostasis.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
